These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 35925819)

  • 1. Searching for Novel Anaplastic Lymphoma Kinase Inhibitors: Structure-Guided Screening of Natural Compounds for a Tyrosine Kinase Therapeutic Target in Cancers.
    Adnan M; Koli S; Mohammad T; Siddiqui AJ; Patel M; Alshammari N; Bardakci F; Elasbali AM; Hassan MI
    OMICS; 2022 Aug; 26(8):461-470. PubMed ID: 35925819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of Potent ALK Inhibitors Using Pharmacophore-Informatics Strategy.
    James N; Ramanathan K
    Cell Biochem Biophys; 2018 Jun; 76(1-2):111-124. PubMed ID: 28477056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anaplastic lymphoma kinase as a therapeutic target in anaplastic large cell lymphoma, non-small cell lung cancer and neuroblastoma.
    Cheng M; Ott GR
    Anticancer Agents Med Chem; 2010 Mar; 10(3):236-49. PubMed ID: 20406193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Computer - Aided Drug Designing for Pharmacological Inhibition of Mutant ALK for the Treatment of Non-small Cell Lung Cancer.
    Sharda S; Khandelwal R; Adhikary R; Sharma D; Majhi M; Hussain T; Nayarisseri A; Singh SK
    Curr Top Med Chem; 2019; 19(13):1129-1144. PubMed ID: 31109278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An updated patent review of anaplastic lymphoma kinase inhibitors (2018-2022).
    Ma D; Guo M; Zhai X
    Expert Opin Ther Pat; 2023 Apr; 33(4):323-337. PubMed ID: 37208827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers.
    Cheng M; Quail MR; Gingrich DE; Ott GR; Lu L; Wan W; Albom MS; Angeles TS; Aimone LD; Cristofani F; Machiorlatti R; Abele C; Ator MA; Dorsey BD; Inghirami G; Ruggeri BA
    Mol Cancer Ther; 2012 Mar; 11(3):670-9. PubMed ID: 22203728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Density Functional Theory and Molecular Simulation Studies for Prioritizing Anaplastic Lymphoma Kinase Inhibitors.
    James N; Shanthi V; Ramanathan K
    Appl Biochem Biotechnol; 2020 Apr; 190(4):1127-1146. PubMed ID: 31712989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug Design for ALK-Positive NSCLC: an Integrated Pharmacophore-Based 3D QSAR and Virtual Screening Strategy.
    James N; Shanthi V; Ramanathan K
    Appl Biochem Biotechnol; 2018 May; 185(1):289-315. PubMed ID: 29134510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK).
    Zhang C; Han XR; Yang X; Jiang B; Liu J; Xiong Y; Jin J
    Eur J Med Chem; 2018 May; 151():304-314. PubMed ID: 29627725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent Updates on Structural Aspects of ALK Inhibitors as an Anticancer Agent.
    Ayaz MS; Bhupal R; Sharma P; Sahu A; Singh P; Gupta GD; Asati V
    Anticancer Agents Med Chem; 2023; 23(8):900-921. PubMed ID: 36627781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors.
    McDermott U; Iafrate AJ; Gray NS; Shioda T; Classon M; Maheswaran S; Zhou W; Choi HG; Smith SL; Dowell L; Ulkus LE; Kuhlmann G; Greninger P; Christensen JG; Haber DA; Settleman J
    Cancer Res; 2008 May; 68(9):3389-95. PubMed ID: 18451166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New perspectives for targeting therapy in ALK-positive human cancers.
    Zhao S; Li J; Xia Q; Liu K; Dong Z
    Oncogene; 2023 Jun; 42(24):1959-1969. PubMed ID: 37149665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The selective anaplastic lymphoma receptor tyrosine kinase inhibitor ASP3026 induces tumor regression and prolongs survival in non-small cell lung cancer model mice.
    Mori M; Ueno Y; Konagai S; Fushiki H; Shimada I; Kondoh Y; Saito R; Mori K; Shindou N; Soga T; Sakagami H; Furutani T; Doihara H; Kudoh M; Kuromitsu S
    Mol Cancer Ther; 2014 Feb; 13(2):329-40. PubMed ID: 24419060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug Discovery Targeting Anaplastic Lymphoma Kinase (ALK).
    Kong X; Pan P; Sun H; Xia H; Wang X; Li Y; Hou T
    J Med Chem; 2019 Dec; 62(24):10927-10954. PubMed ID: 31419130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Virtual screening and further development of novel ALK inhibitors.
    Okamoto M; Kojima H; Saito N; Okabe T; Masuda Y; Furuya T; Nagano T
    Bioorg Med Chem; 2011 May; 19(10):3086-95. PubMed ID: 21515061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ALK inhibitors in the treatment of advanced NSCLC.
    Gridelli C; Peters S; Sgambato A; Casaluce F; Adjei AA; Ciardiello F
    Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of novel anaplastic lymphoma kinase (ALK) inhibitors using a common feature pharmacophore model derived from known ligands crystallized with ALK.
    Xie HZ; Lan H; Pan YL; Zou J; Wang ZR; Li LL; Huang Q; Zhang H; Yang SY
    Chem Biol Drug Des; 2013 Feb; 81(2):175-84. PubMed ID: 23107363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of novel chemotype inhibitors targeting Anaplastic Lymphoma Kinase receptor through ligand-based pharmacophore modelling.
    El-Jundi I; Daoud S; Taha MO
    SAR QSAR Environ Res; 2024 Sep; 35(9):795-815. PubMed ID: 39382553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine.
    Katayama R; Lovly CM; Shaw AT
    Clin Cancer Res; 2015 May; 21(10):2227-35. PubMed ID: 25979929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent Development in the Discovery of Anaplastic Lymphoma Kinase (ALK) Inhibitors for Non-small Cell Lung Cancer.
    Liu J; Ma S
    Curr Med Chem; 2017; 24(6):590-613. PubMed ID: 27804873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.